መነሻ › ዲፊዩዝ ላርጅ ቢ-ሴል ሊምፎማ › South Carolina
በSouth Carolina ለዲፊዩዝ ላርጅ ቢ-ሴል ሊምፎማ የሚደረጉ ክሊኒካዊ ጥናቶች
ለዲፊዩዝ ላርጅ ቢ-ሴል ሊምፎማ የሚደረጉ 4 ጥናቶች በSouth Carolina ባሉ ቦታዎች ተሳታፊዎችን እየፈለጉ ነው።
በSouth Carolina ውስጥ ያሉ ከተሞች
Official study text (English)
A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)
- Prisma Health - Upstate ( Site 0158), Greenville
ተሳታዮችን በመፈለግ ላይደረጃ 3
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06717347A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
- Medical University of South Carolina ( Site 0153), Charleston
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ25 ሴፕቴ 2026 · NCT06890884Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
- Prisma Health Cancer Institute - Spartanburg, Boiling Springs
- Medical University of South Carolina, Charleston
- Prisma Health Cancer Institute - Easley, Easley
- እና 5 ተጨማሪ
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ2 ፌብሩ 2026 · NCT05633615Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment
- Medical University of South Carolina, Charleston
ተሳታዮችን በመፈለግ ላይደረጃ 2
እድሜ 18 እና ከዚያ በላይ · ሁሉም ጾታዎች · የተሻሻለው በ20 ኦክቶ 2025 · NCT05890352ከ ClinicalTrials.gov የተገኘ መረጃ፣ በ5 ኦክቶ 2026 የተሰብሰቡ። እያንዳንዱ ጥናት የራሱን ቅድመ ሁኔታ ይወስናል፤ የጥናት ቡድኑ ማን መሳተፍ እንደሚችል ይወስናል።